Cefazolin pharmacokinetics during prolonged intermittent kidney replacement therapy
Acute kidney injury is a frequent complication in critically ill patients and often necessitates kidney replacement therapy. Optimising antimicrobial dosing in this population is essential yet challenging owing to altered pharmacokinetics in critical illness and the wide variability of prescriptions utilised in kidney replacement therapy. This case report investigates the pharmacokinetics of cefazolin in a critically ill patient receiving prolonged intermittent kidney replacement therapy, offering insights into dosing considerations in this clinical setting.
Authors
- David Morgan (ORCID: https://orcid.org/0000-0002-7410-6591)
- John R. Dyer (ORCID: https://orcid.org/0000-0002-3874-3163)
- Jessica H Xu (ORCID: https://orcid.org/0009-0004-5134-1996)
- Matthew Rawlins (ORCID: https://orcid.org/0000-0002-6525-1084)
- Hayoung Won (ORCID: https://orcid.org/0000-0002-9248-5134)
- Sam Salman (ORCID: https://orcid.org/0000-0002-8276-6784)
- Steven C. Wallis (ORCID: https://orcid.org/0000-0002-2392-9854)
- Jason Roberts (ORCID: https://orcid.org/0000-0002-9734-9764)
Institutions
- The University of Queensland (AU)
- The University of Western Australia (AU)
- Curtin University (AU)
- Royal Brisbane and Women's Hospital (AU)
- Fiona Stanley Hospital (AU)
- Metro South Health (AU)
- Pathwest Laboratory Medicine (AU)
- Université de Nîmes (FR)
Publication Details
- Journal
- Anaesthesia and Intensive Care
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1177/0310057x251396229
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00